

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	244	564/84	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L2	436	564/86	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L3	658	514/602	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L4	400	514/604	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:04

## EAST Search History



Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	244	564/84	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L2	436	564/86	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L3	658	514/602	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L4	400	514/604	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:04

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13	(("5756533") or ("5776971") or ("6046190") or ("6143788") or ("6150556") or ("6156768") or ("6391919")).PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:32
L2	0	David.inv. and carnii.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38
L3	58	David.inv. and carini.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13	(("5756533") or ("5776971") or ("6046190") or ("6143788") or ("6150556") or ("6156768") or ("6391919")).PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:32
L2	0	David.inv. and carnii.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38
L3	58	David.inv. and carini.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20 21 22 23 24 25 26 29 30

ring nodes :

17 33 34 35 36 37

chain bonds :

1-2 1-29 2-3 2-4 2-5 3-30 5-6 6-7 7-8 7-9 9-10 10-11 10-12 12-13 12-14 14-15 15-16  
15-18 16-17 18-19 18-20 19-26 20-21 21-22 22-23 22-24 22-25

ring bonds :

17-33 17-37 33-34 34-35 35-36 36-37

exact/norm bonds :

2-4 2-5 5-6 7-8 7-9 9-10 10-11 12-13 12-14 14-15 18-19 20-21 21-22 22-23 22-24 22-25

exact bonds :

1-2 1-29 2-3 3-30 6-7 10-12 15-16 15-18 16-17 18-20 19-26

normalized bonds :

17-33 17-37 33-34 34-35 35-36 36-37

isolated ring systems :

containing 17 :

Match level :

1:CLASS2:CLASS3:CLASS4:Atom 5:CLASS6:CLASS7:CLASS8:CLASS9:CLASS10:CLASS11:CLASS12:CLASS13:CLASS14:CLASS15:CLASS16:CLASS17:Atom 18:CLASS19:CLASS20:CLASS21:CLASS22:CLASS23:CLASS24:CLASS25:Atom 26:CLASS29:CLASS30:CLASS33:Atom 34:Atom 35:Atom 36:Atom 37:Atom

Generic attributes :

4:

Saturation : Unsaturated

Type of Ring System : Monocyclic

25:

Saturation : Unsaturated

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1611bxv

**PASSWORD:**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records  
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation  
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme  
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 13 OCT 19 E-mail format enhanced  
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded  
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced  
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available  
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role  
NEWS 22 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases  
NEWS 23 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000  
NEWS 24 NOV 20 CA/CAplus patent kind codes will be updated  
NEWS 25 DEC 01 CAS REGISTRY updated with new ambiguity codes

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:26:04 ON 08 DEC 2006

=> file reg

**COST IN U.S. DOLLARS**

SINCE FILE

**TOTAL**

**FULL ESTIMATED COST**

ENTRI  
0.21

SESSION  
0.21

FILE 'REGISTRY' ENTERED AT 07:26:12 ON 08 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

**STRUCTURE FILE UPDATES:** 7 DEC 2006 **HIGHEST RN** 915067-95-7  
**DICTIONARY FILE UPDATES:** 7 DEC 2006 **HIGHEST RN** 915067-95-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

$\Rightarrow$

Uploading C:\Program Files\Stnexp\Queries\107002781.str



chain nodes :

10/700,278

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20 21 22 23 24  
25 26 29 30  
ring nodes :  
17 33 34 35 36 37  
chain bonds :  
1-2 1-29 2-3 2-4 2-5 3-30 5-6 6-7 7-8 7-9 9-10 10-11 10-12 12-13  
12-14 14-15 15-16 15-18 16-17 18-19 18-20 19-26 20-21 21-22 22-23 22-24  
22-25  
ring bonds :  
17-33 17-37 33-34 34-35 35-36 36-37  
exact/norm bonds :  
2-4 2-5 5-6 7-8 7-9 9-10 10-11 12-13 12-14 14-15 18-19 20-21 21-22  
22-23 22-24 22-25  
exact bonds :  
1-2 1-29 2-3 3-30 6-7 10-12 15-16 15-18 16-17 18-20 19-26  
normalized bonds :  
17-33 17-37 33-34 34-35 35-36 36-37  
isolated ring systems :  
containing 17 :

Match level :  
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom  
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom  
26:CLASS 29:CLASS 30:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom  
Generic attributes :  
4:  
Saturation : Unsaturated  
Type of Ring System : Monocyclic  
25:  
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR  
\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam  
SAMPLE SEARCH INITIATED 07:26:39 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 346 TO 1054  
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

10/700,278


=> d scan

10/700,278


L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-(methylthio)-(9CI)  
MF C40 H52 F N5 O5 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10/700,278

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN L-Valinamide, N-[1-(4-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI)  
MF C37 H52 F N5 O5 S

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/700,278

=> s 11 sss ful  
FULL SEARCH INITIATED 07:26:56 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 639 TO ITERATE

100.0% PROCESSED 639 ITERATIONS 32 ANSWERS  
SEARCH TIME: 00.00.01

L3 32 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
166.94 167.15

FILE 'CAPLUS' ENTERED AT 07:27:01 ON 08 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2006 VOL 145 ISS 25  
FILE LAST UPDATED: 7 Dec 2006 (20061207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 13  
L4 1 L3

=> d 14 bib hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:430693 CAPLUS  
DN 140:407115  
TI Preparation of  $\alpha,\alpha$ -disubstituted benzylglycine derivatives as HIV protease inhibitors  
IN Carini, David J.  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 81 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043355	A2	20040527	WO 2003-US35035	20031104
	WO 2004043355	A3	20040826		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2006128634	A1	20060615	US 2003-700278	20031103
	AU 2003291710	A1	20040603	AU 2003-291710	20031104
PRAI	US 2002-426223P	P	20021114		
	WO 2003-US35035	W	20031104		
OS	MARPAT 140:407115				
IT	689232-07-3P 689232-31-3P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of $\alpha,\alpha$ -disubstituted benzylglycine derivs. as HIV protease inhibitors)				
RN	689232-07-3 CAPLUS				
CN	L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




● x HCl

RN 689232-31-3 CAPLUS  
CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-

(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

IT 689232-08-4P 689232-09-5P 689232-10-8P  
 689232-11-9P 689232-12-0P 689232-13-1P  
 689232-14-2P 689232-15-3P 689232-16-4P  
 689232-17-5P 689232-18-6P 689232-19-7P  
 689232-20-0P 689232-21-1P 689232-23-3P  
 689232-25-5P 689232-27-7P 689232-29-9P  
 689232-33-5P 689232-35-7P 689232-37-9P  
 689232-39-1P 689232-41-5P 689232-44-8P  
 689232-46-0P 689232-48-2P 689232-50-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\alpha,\alpha$ -disubstituted benzylglycine derivs. as HIV protease inhibitors)

RN 689232-08-4 CAPLUS

CN L-Valinamide, N-[1-(4-aminophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-09-5 CAPLUS

CN L-Valinamide, N-[1-(4-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-10-8 CAPLUS

CN L-Valinamide, N-[1-(3,5-difluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-11-9 CAPLUS

CN L-Valinamide, N-[1-(3-methoxyphenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OMe

RN 689232-12-0 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-13-1 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● x HCl


PAGE 1-B



RN 689232-14-2 CAPLUS

CN L-Valinamide, N-[1-methyl-1-phenylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/700,278

RN 689232-15-3 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-16-4 CAPLUS


CN L-Isoleucinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-17-5 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(1H-indazol-6-ylsulfonyl)(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-18-6 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

PAGE 1-A



PAGE 1-B




RN 689232-19-7 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

PAGE 1-A



PAGE 1-B




RN 689232-20-0 CAPLUS


CN L-Isoleucinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 689232-21-1 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-23-3 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B



RN 689232-25-5 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)glycyl-N-[(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-27-7 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(3-amino-4-methylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 689232-29-9 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 689232-33-5 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-35-7 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-37-9 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-39-1 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-β-alanyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-41-5 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-44-8 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-46-0 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 689232-48-2 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(3-amino-4-methylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 689232-50-6 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






IT 689232-72-2P 689232-76-6P 689232-81-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of  $\alpha,\alpha$ -disubstituted benzylglycine derivs. as HIV protease inhibitors)  
 RN 689232-72-2 CAPLUS  
 CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-76-6 CAPLUS  
 CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 689232-81-3 CAPLUS  
 CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/700,278

=> log y	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	3.97	171.12

STN INTERNATIONAL LOGOFF AT 07:27:38 ON 08 DEC 2006